SCHEMBL4773950

SCHEMBL4773950

N#Cc1cnc2cnc(NCc3cccnc3)cc2c1Nc1ccccc1

nearest known ligand 0.74

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP3K8 P41279 12/20 0.74
MAPK13 O15264 4/20 0.74
MAPK12 P53778 4/20 0.74
MAPK11 Q15759 4/20 0.74
MAPK14 Q16539 4/20 0.74
EIF2AK2 P19525 1/20 0.74
SRC P12931 4/20 0.68
MAP2K1 Q02750 6/20 0.56
EGFR P00533 1/20 0.52
ABCB1 P08183 1/20 0.51
ABCC1 P33527 1/20 0.51
ABCG2 Q9UNQ0 1/20 0.51
LTA4H P09960 1/20 0.46
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767287 0.98 MAP3K8 (0.75) MAP3K8MAPK13MAPK12MAPK11MAPK14
SCHEMBL5111303 0.92 MAP3K8 (0.69) MAP3K8MAPK13MAPK12MAPK11MAPK14
SCHEMBL5124439 0.91 MAP3K8 (0.73) MAP3K8MAPK13MAPK12MAPK11MAPK14
SCHEMBL4904414 0.91 MAP3K8 (0.82) MAP3K8MAPK13MAPK12MAPK11MAPK14
SCHEMBL4769727 0.91 MAP3K8 (0.79) MAP3K8MAPK13MAPK12MAPK11MAPK14
SCHEMBL5111372 0.90 MAP3K8 (0.67) MAP3K8MAPK13MAPK12MAPK11MAPK14
SCHEMBL5124937 0.90 MAP3K8 (0.71) MAP3K8MAPK13MAPK12MAPK11MAPK14
SCHEMBL4766912 0.90 MAP3K8 (0.79) MAP3K8MAPK13MAPK12MAPK11MAPK14
SCHEMBL5124454 0.89 MAP3K8 (0.79) MAP3K8MAPK13MAPK12MAPK11MAPK14
SCHEMBL5118168 0.88 MAP3K8 (0.85) MAP3K8MAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432279-B2 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2008-10-07 US disclosed
EP-1881981-A1 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME Wyeth (US) 2008-01-30 EP disclosed
US-20060276498-A1 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same WYETH (US) 2006-12-07 US disclosed
WO-2006124944-A1 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276498-A1 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same TNNI3K, CNKSR1, DTYMK MAP3K8 99/4885MAPK13 404/4885MAPK12 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.